Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Episode 26 with Dr. Tim Kennedy on remyelination and oligodendrocyte development
Covis Pharma to Acquire U.S. Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate®
Episode 16 with Dr. Revere [double-quote]Rip[double-quote] Kinkel on how to improve patient outreach
Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial
Bilateral optic neuritis in a patient with Behçet's disease who respond to therapeutic plasma exchange.
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study.
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.
Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner.
Myelin Oligodendrocyte Glycoprotein-Associated Pediatric Central Nervous System Demyelination: Clinical Course, Neuroimaging Findings, and Response to Therapy.
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Breastfeeding and multiple sclerosis relapses: a meta-analysis.
Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016.
Synthetic Biologics announces issuance of U.S. patent covering combination of estriol and Copaxone® for multiple sclerosis
European School of Neuroimmunology 15th Course
Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis.
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation.
Multiple sclerosis: pathogenesis and treatment.
Avonex approval application
Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study.
Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica.
Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.
Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment.
Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis.
12th International Conference on Myasthenia Gravis and Related Disorders
Randomized study combining interferon & glatiramer acetate in multiple sclerosis.

Pages